At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug coated balloons (DCB) have shown benefits in restenosis and small vessel de novo lesions. Intravascular ultrasound (IVUS) has been shown effective in left main PCI and complex procedures, even though there is little infomration on its use for<a href="https://solaci.org/en/2024/06/12/coronary-angioplasty-with-sirolimus-eluting-stents/" title="Read more" >...</a>
In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a prevalence between 5% and 10% after implantation of latest-generation drug-eluting stents (DES). Therapeutic recommendations for it include the implantation of a new DES and the use of drug-coated balloons (DCB). The rate of recurrent ISR ranges from 10%<a href="https://solaci.org/en/2024/04/29/treatment-of-recurrent-in-stent-restenosis-with-drug-eluting-stents-10-year-outcomes/" title="Read more" >...</a>
The impact of diabetes on the development of cardiovascular disease is widely known, with a strong association with extensive and diffuse coronary artery disease. Decision-making regarding how to revascularize patients with multi-vessel disease is a complex process. In this context, coronary artery bypass grafting (CABG) has been recommended over percutaneous coronary intervention (PCI) based on<a href="https://solaci.org/en/2023/10/31/long-term-results-from-the-best-study-drug-eluting-stents-vs-bypass-surgery-in-diabetic-patients-with-multiple-vessel-disease/" title="Read more" >...</a>
Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients. The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total<a href="https://solaci.org/en/2023/10/19/ultrathin-stents-shown-safe-and-effective-in-real-world-patients/" title="Read more" >...</a>
Coronary bifurcation lesions have been a subject to debate, with different approaches by various medical teams. These lesions often carry a higher risk of ischemic events compared with lesions at non-bifurcated sites. The main strategy, supported by medical society recommendations and clinical guidelines, involves using provisional stenting with one stent to minimize the number of<a href="https://solaci.org/en/2023/10/04/bifurcat-registry-1-or-2-stents-treatment-of-side-branch-medina-0-0-1-lesions-according-to-real-world-data/" title="Read more" >...</a>
Calcified coronary plaque (CCP) is a challenge for interventional cardiology. Stent underexpansion (SU) commonly associated with CCP could predispose to stent thrombosis or restenosis. Currently, SU in severe CCP can be treated by rotational atherectomy, orbital atherectomy, balloon cutting/scoring, non-compliant high-pressure balloons, or intravascular lithotripsy (IVL). The aim of this meta-analysis was to determine the<a href="https://solaci.org/en/2023/05/22/europcr-2023-intravascular-lithotripsy-ivl-balloon-in-the-treatment-of-underexpanded-stents/" title="Read more" >...</a>
The EBC MAIN LM study randomized 467 patients with severe left main coronary artery (LCA) lesions to receive provisional stenting or a two-sent strategy (Resolute or Onix stent). The two-stent strategy was decided by the operator (culotte, DK-minicrush, T/TAP). The crossover rate from those randomized to provisional stenting was 22%. After a 3-year follow-up, the composite<a href="https://solaci.org/en/2023/05/21/europcr-2023-left-main-coronary-artery-angioplasty-one-or-two-stents/" title="Read more" >...</a>
By Dr. Carlos Zabal.
Percutaneous coronary intervention (PCI) to the left main coronary artery (LMCA) with drug-eluting stent implantation is currently a major challenge due to the size of the vessel, the compromise of a bifurcation lesion in important branches, and the potential risk of complications. Available information on LMCA PCI comes from studies where DES stents were implanted<a href="https://solaci.org/en/2023/01/18/left-main-coronary-artery-pci-using-state-of-the-art-zotarolimus-eluting-stents/" title="Read more" >...</a>
Enjoy this master conference given by Dr. Roxana Mehran during the SOLACI-SOCIME 2022 Congress held at Expo Santa Fé, CDMX on August 4, 5 and 6, 2022. Topic: Advances in the design of STENTS in PCI: DIABETES MELLITUS.